Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 nov. 2025 09h00 HE | Source: Muscular Dystrophy Association

Muscular Dystrophy Association Names Sharon Hesterlee, PhD, as President and Chief Executive Officer

New York, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced the appointment of Sharon Hesterlee, PhD as President and Chief Executive Officer. Dr. Hesterlee...
03 nov. 2025 17h25 HE | Source: Muscular Dystrophy Association

FDA Approves KYGEVVI® (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 deficiency (TK2d), a Rare and Devastating Mitochondrial Disease

New York, Nov. 03, 2025 (GLOBE NEWSWIRE) -- New York, Monday, November 3, 2025 – The Muscular Dystrophy Association (MDA) marks another milestone today in our legacy of progress with the FDA...
03 nov. 2025 09h00 HE | Source: Muscular Dystrophy Association

Muscular Dystrophy Association Honors National Family Caregivers Month with Advocacy and Awareness Nationwide

New York, Nov. 03, 2025 (GLOBE NEWSWIRE) -- This November, the Muscular Dystrophy Association (MDA) is honoring family caregivers who provide essential support for people living with muscular...
20 oct. 2025 09h00 HE | Source: Muscular Dystrophy Association

Muscular Dystrophy Association Launches Holiday Retail Campaign in Thousands of Retail Locations Nationwide

New York, Oct. 20, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today kicked off its largest annual MDA Holiday Retail Campaign, spanning thousands of retail locations...
15 oct. 2025 09h00 HE | Source: Muscular Dystrophy Association

Agenda Announced for 2026 MDA Clinical & Scientific Conference Featuring Leading Speakers Dedicated to Groundbreaking Research and Clinical Achievements in Neuromuscular Disease

New York, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced the agenda including tracks and chairs for the 2026 MDA Clinical & Scientific Conference...
05 sept. 2025 07h00 HE | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

Entrada Therapeutics announces the recipients of its third annual DREAMS Grant Program.
25 août 2025 09h00 HE | Source: Muscular Dystrophy Association

Muscular Dystrophy Association Launches #MDAstrong Campaign in September During Historic 75th Anniversary, Kicking Off on Labor Day Weekend

New York, Aug. 25, 2025 (GLOBE NEWSWIRE) -- This September, the Muscular Dystrophy Association (MDA) is launching its milestone #MDAstrong campaign during a historic moment for the organization: its...
23 août 2025 16h42 HE | Source: Muscular Dystrophy Association

Muscular Dystrophy Association and Parent Project Muscular Dystrophy Announce Joint Consensus Guidelines for Safe and Equitable Delivery of Gene Therapy in Duchenne Muscular Dystrophy

New York, Aug. 23, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) and Parent Project Muscular Dystrophy (PPMD) today announced the publication of jointly developed consensus...
06 août 2025 07h00 HE | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

Entrada Therapeutics reports financial results for the second quarter ended June 30, 2025, and highlights recent business updates.
30 juil. 2025 09h00 HE | Source: Muscular Dystrophy Association

Registration Now Open for the 2026 MDA Clinical & Scientific Conference Where Global Leaders in Neuromuscular Disease Research & Care Unite to Drive the Next Breakthroughs March 8-11 in Orlando, FL

New York, July 30, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), leader and innovator of the largest global gathering of the neuromuscular disease community, announced today...

Page suivante